MAPT and early-onset autosomal dominant Alzheimer disease: The drug modulates the PI3K/Akt/GSK-3β signaling pathway, critical for glucose metabolism and tau protein phosphorylation, both of which are disrupted in diabetes and Alzheimer’s disease.